Sage Halts Alzheimer's Drug Dalzanemdor, Shifts Focus to Huntington's Amid Challenges
Sage Therapeutics has decided to halt the development of its Alzheimer’s drug, dalzanemdor, after disappointing results from a Phase II trial that showed no significant cognitive improvement over a placebo. The trial involved 174 patients and used the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) as a primary measure[1][3]. This setback follows a previous failure of dalzanemdor in a Parkinson’s trial, leading the company to shift focus to Huntington's disease, where trials continue despite limited expectations[2][3].
References
Explore Further
What were the specific reasons for the failure of dalzanemdor in the Phase II trials for Alzheimer's disease?
How does Sage Therapeutics plan to address its financial challenges following the discontinuation of dalzanemdor for Alzheimer's?
What are the distinct pathophysiological aspects of Huntington's disease that make Sage optimistic about dalzanemdor's potential effectiveness?
How might the past failures in Parkinson's and Alzheimer's trials influence the design and expectations for the Huntington's trials?
What strategic changes might Sage need to implement to improve profitability given the recent trial setbacks?